BACKGROUND: Sickle cell disease (SCD) is a complex chronic disease requiring multidisciplinary care that involves primary care physicians (PCPs) working with a hematologist or SCD specialists. However, PCPs often lack access to SCD specialists and are unaware of SCD guidelines or efficacious treatment. METHODS: We partnered with Community Care of North Carolina (CCNC) to identify assigned PCPs for SCD patients with Medicaid across North Carolina. CCNC network administrators distributed a web-based questionnaire for completion. The questionnaire involved 12 self-reported items on a yes-no or a 1 to 5 Likert-type scale that assessed PCP attitudes toward SCD care, awareness of recent guidelines, and comanaging hydroxyurea. RESULTS: Of the 53 PCPs who completed the electronic survey, 73% felt they were comfortable with the number of SCD patients in their practice. Most PCPs reported having infrequent communications with an SCD specialist (67%) and most were also not aware of the 2014 SCD guidelines (66%). Many reported that they would frequently use the new SCD guidelines if provided to them (76%). Furthermore, 51% of PCPs expressed comfort with using mobile apps to access SCD guidelines and provided email contact to receive further information. The majority also reported being comfortable comanaging hydroxyurea with an SCD specialist (65%). CONCLUSION: Few PCPs in North Carolina were aware of the new SCD guidelines or had regular communication with an SCD specialist. The majority of PCPs, however, demonstrated a favorable attitude toward receiving the SCD guidelines and comanaging hydroxyurea with a specialist. In response to this gap in care, we have developed a mobile-based SCD toolbox specifically for PCPs to provide guidelines, algorithms, and a method to communicate with local SCD specialists. With the interest in receiving these guidelines, we are confident the toolbox will provide an easy to use platform to assist PCPs to utilize the SCD guidelines.
BACKGROUND:Sickle cell disease (SCD) is a complex chronic disease requiring multidisciplinary care that involves primary care physicians (PCPs) working with a hematologist or SCD specialists. However, PCPs often lack access to SCD specialists and are unaware of SCD guidelines or efficacious treatment. METHODS: We partnered with Community Care of North Carolina (CCNC) to identify assigned PCPs for SCD patients with Medicaid across North Carolina. CCNC network administrators distributed a web-based questionnaire for completion. The questionnaire involved 12 self-reported items on a yes-no or a 1 to 5 Likert-type scale that assessed PCP attitudes toward SCD care, awareness of recent guidelines, and comanaging hydroxyurea. RESULTS: Of the 53 PCPs who completed the electronic survey, 73% felt they were comfortable with the number of SCD patients in their practice. Most PCPs reported having infrequent communications with an SCD specialist (67%) and most were also not aware of the 2014 SCD guidelines (66%). Many reported that they would frequently use the new SCD guidelines if provided to them (76%). Furthermore, 51% of PCPs expressed comfort with using mobile apps to access SCD guidelines and provided email contact to receive further information. The majority also reported being comfortable comanaging hydroxyurea with an SCD specialist (65%). CONCLUSION: Few PCPs in North Carolina were aware of the new SCD guidelines or had regular communication with an SCD specialist. The majority of PCPs, however, demonstrated a favorable attitude toward receiving the SCD guidelines and comanaging hydroxyurea with a specialist. In response to this gap in care, we have developed a mobile-based SCD toolbox specifically for PCPs to provide guidelines, algorithms, and a method to communicate with local SCD specialists. With the interest in receiving these guidelines, we are confident the toolbox will provide an easy to use platform to assist PCPs to utilize the SCD guidelines.
Authors: Sarah L Reeves; Heather J Fullerton; Kevin J Dombkowski; Matthew L Boulton; Thomas M Braun; Lynda D Lisabeth Journal: Clin Pediatr (Phila) Date: 2014-10-15 Impact factor: 1.168
Authors: Megumi J Okumura; Michele Heisler; Matthew M Davis; Michael D Cabana; Sonya Demonner; Eve A Kerr Journal: J Gen Intern Med Date: 2008-07-26 Impact factor: 5.128
Authors: Lauren N Whiteman; Carlton Haywood; Sophie Lanzkron; John J Strouse; Leonard Feldman; Rosalyn W Stewart Journal: South Med J Date: 2015-09 Impact factor: 0.954
Authors: Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah Journal: JAMA Date: 2014-09-10 Impact factor: 56.272
Authors: Nancy Crego; Christian Douglas; Emily Bonnabeau; Marian Earls; Kern Eason; Elizabeth Merwin; Gary Rains; Paula Tanabe; Nirmish Shah Journal: J Am Board Fam Med Date: 2020 Jan-Feb Impact factor: 2.657
Authors: Amol Utrankar; Tilicia L Mayo-Gamble; Whitney Allen; Laurie Novak; Adetola A Kassim; Kemberlee Bonnet; David Schlundt; Velma M Murry; Gretchen Purcell Jackson; Michael DeBaun; Robert M Cronin Journal: J Am Med Inform Assoc Date: 2018-08-01 Impact factor: 4.497
Authors: Robert Michael Cronin; Tilicia L Mayo-Gamble; Sarah-Jo Stimpson; Sherif M Badawy; Lori E Crosby; Jeannie Byrd; Emmanuel J Volanakis; Adetola A Kassim; Jean L Raphael; Velma M Murry; Michael R DeBaun Journal: BMC Hematol Date: 2018-06-08
Authors: Benjamin Tolchin; Gaston Baslet; Alan Carson; Barbara A Dworetzky; Laura H Goldstein; W Curt LaFrance; Steve Martino; David L Perez; Markus Reuber; Jon Stone; Jerzy P Szaflarski Journal: Epilepsy Behav Rep Date: 2021-10-21